Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Madrigal Pharmaceuticals (MDGL) EBT Margin (2019 - 2025)

Historic EBT Margin for Madrigal Pharmaceuticals (MDGL) over the last 6 years, with Q3 2025 value amounting to 38.68%.

  • Madrigal Pharmaceuticals' EBT Margin rose 1333600.0% to 38.68% in Q3 2025 from the same period last year, while for Sep 2025 it was 38.62%, marking a year-over-year increase of 6366200.0%. This contributed to the annual value of 258.64% for FY2024, which is N/A changed from last year.
  • Per Madrigal Pharmaceuticals' latest filing, its EBT Margin stood at 38.68% for Q3 2025, which was up 1333600.0% from 19.85% recorded in Q2 2025.
  • In the past 5 years, Madrigal Pharmaceuticals' EBT Margin registered a high of 19.85% during Q2 2025, and its lowest value of 1038.2% during Q2 2024.